These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 16625226)

  • 21. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome.
    Malloy CA; Nicoski P; Muraskas JK
    Acta Paediatr; 2005 Jun; 94(6):779-84. PubMed ID: 16188788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Animal-derived surfactant treatment of respiratory distress syndrome in premature neonates: a review.
    Fujii AM; Carillo M
    Drugs Today (Barc); 2009 Sep; 45(9):697-709. PubMed ID: 19956811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bovine or Porcine: Does the Type of Surfactant Matter?
    Boshoff Coyles L; Joolay Y; Tooke L
    J Trop Pediatr; 2020 Oct; 66(5):534-541. PubMed ID: 32112649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome.
    Bahadue FL; Soll R
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD001456. PubMed ID: 23152207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome. A postmarketing phase IV study.
    Lamboley-Gilmert G; Lacaze-Masmonteil T;
    Paediatr Drugs; 2003; 5(9):639-45. PubMed ID: 12956620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of a new technique - INtubate-RECruit-SURfactant-Extubate - "IN-REC-SUR-E" - in preterm neonates with respiratory distress syndrome: study protocol for a randomized controlled trial.
    Vento G; Pastorino R; Boni L; Cota F; Carnielli V; Cools F; Dani C; Mosca F; Pillow J; Polglase G; Tagliabue P; van Kaam AH; Ventura ML; Tana M; Tirone C; Aurilia C; Lio A; Ricci C; Gambacorta A; Consigli C; D'Onofrio D; Gizzi C; Massenzi L; Cardilli V; Casati A; Bottino R; Pontiggia F; Ciarmoli E; Martinelli S; Ilardi L; Colnaghi M; Matassa PG; Vendettuoli V; Villani P; Fusco F; Gazzolo D; Ricotti A; Ferrero F; Stasi I; Magaldi R; Maffei G; Presta G; Perniola R; Messina F; Montesano G; Poggi C; Giordano L; Roma E; Grassia C; Ausanio G; Sandri F; Mescoli G; Giura F; Garani G; Solinas A; Lucente M; Nigro G; Del Vecchio A; Petrillo F; Orfeo L; Grappone L; Quartulli L; Scorrano A; Messner H; Staffler A; Gargano G; Balestri E; Nobile S; Cacace C; Meli V; Dallaglio S; Pasqua B; Mattia L; Gitto E; Vitaliti M; Re MP; Vedovato S; Grison A; Berardi A; Torcetta F; Guidotti I; di Fabio S; Maranella E; Mondello I; Visentin S; Tormena F
    Trials; 2016 Aug; 17():414. PubMed ID: 27538798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. History of surfactant from 1980.
    Halliday HL
    Biol Neonate; 2005; 87(4):317-22. PubMed ID: 15985754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Less invasive surfactant administration versus endotracheal surfactant instillation followed by limited peak pressure ventilation in preterm infants with respiratory distress syndrome in China: study protocol for a randomized controlled trial.
    Zhu J; Bao Y; Du L; Huang H; Lv Q; Jiang Y; Dai Y; Chen Z; Shi J; Shi Y; Yang C; Mei H; Jiang H; Sun Y; Sun X
    Trials; 2020 Jun; 21(1):516. PubMed ID: 32527290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perfusion index variability in preterm infants treated with two different natural surfactants for respiratory distress syndrome.
    Karadag N; Dilli D; Zenciroglu A; Aydin B; Beken S; Okumus N
    Am J Perinatol; 2014 Nov; 31(11):1015-22. PubMed ID: 24566756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effectiveness of surfactant preparations in premature infants.
    Trembath A; Hornik CP; Clark R; Smith PB; Daniels J; Laughon M;
    J Pediatr; 2013 Oct; 163(4):955-60.e1. PubMed ID: 23769501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Randomized, Controlled Trial to Investigate the Efficacy of Nebulized Poractant Alfa in Premature Babies with Respiratory Distress Syndrome.
    Dani C; Talosi G; Piccinno A; Ginocchio VM; Balla G; Lavizzari A; Stranak Z; Gitto E; Martinelli S; Plavka R; Krolak-Olejnik B; Lista G; Spedicato F; Ciurlia G; Santoro D; Sweet D;
    J Pediatr; 2022 Jul; 246():40-47.e5. PubMed ID: 35257740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surfactant Treatment Threshold during NCPAP for the Treatment of Preterm Infants with Respiratory Distress Syndrome.
    Dani C
    Am J Perinatol; 2016 Aug; 33(10):925-9. PubMed ID: 27120482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nebulized Poractant Alfa Reduces the Risk of Respiratory Failure at 72 Hours in Spontaneously Breathing Surfactant-Deficient Newborn Piglets.
    Rey-Santano C; Mielgo VE; Gomez-Solaetxe MA; Bianco F; Salomone F; Loureiro B
    Crit Care Med; 2020 Jun; 48(6):e523-e531. PubMed ID: 32301841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surfactant therapy: past, present and future.
    Speer CP; Sweet DG; Halliday HL
    Early Hum Dev; 2013 Jun; 89 Suppl 1():S22-4. PubMed ID: 23809343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On "A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants" (Am J Perinatol 2004;21:109-120).
    Bancalari E
    Am J Perinatol; 2004 Jul; 21(5):307-9. PubMed ID: 15232767
    [No Abstract]   [Full Text] [Related]  

  • 36. Is it feasible to identify preterm infants with respiratory distress syndrome for early extubation to continuous positive airway pressure post-surfactant treatment during retrieval?
    Priyadarshi A; Quek WS; Luig M; Lui K
    J Paediatr Child Health; 2015 Mar; 51(3):321-7. PubMed ID: 25196918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicentre, randomised trial of preterm infants receiving caffeine and less invasive surfactant administration compared with caffeine and early continuous positive airway pressure (CaLI trial): study protocol.
    Ines F; Hutson S; Coughlin K; Hopper A; Banerji A; Uy C; Finer N; Rich W; Morales A; Steen J; Katheria AC
    BMJ Open; 2021 Jan; 11(1):e038343. PubMed ID: 33483435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Timing of surfactant treatment in respiratory distress syndrome.
    van Kaam AH; Niemarkt HJ; Onland W
    Semin Fetal Neonatal Med; 2023 Dec; 28(6):101495. PubMed ID: 38012889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome.
    Pfister RH; Soll R; Wiswell TE
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006180. PubMed ID: 19821357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poractant alfa versus bovine lipid extract surfactant: prospective comparative effectiveness study.
    Lemyre B; Lacaze-Masmonteil T; Shah PS; Bodani J; Doucette S; Dunn M; Louis D; Monterrosa L; Mukerji A; Schmölzer GM; Singh B; Wong J; Ye XY; Offringa M
    J Perinatol; 2022 Apr; 42(4):468-475. PubMed ID: 35177795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.